ASCO GU Conference Coverage
Filter News By:
Featured News
View all
More News
(PMLiVE.com [UK]) Feb 17, 2020 - Bristol-Myers Squibb has unveiled long-term results for Opdivo in renal cell carcinoma, which demonstrated efficacy with and without CTLA4 blocker Yervoy.
(Medscape Medical News) Feb 14, 2020 - Practice-changing studies in cancer care are almost always the result of an improvement in efficacy that "moves the needle," usually in terms of progression-free or overall survival. But here at...
(Medscape Medical News) Feb 17, 2020 - It seemed like a sensible measure for desperate times, but reducing the standard frequency of doses of bacille Calmette-Guérin (BCG; Merck) for the treatment of high-grade bladder cancer resulted in...
(MedPage Today) Feb 15, 2020 - Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data...
(MedPage Today) Feb 17, 2020 - Pairing immunotherapy with stereotactic body radiation therapy (SBRT) produced mixed results in advanced renal cell carcinoma (RCC) in two preliminary trials reported here.
(MedPage Today) Feb 14, 2020 - Immediate treatment of limited metastatic recurrence of prostate cancer led to a fourfold improvement in the proportion of patients alive without androgen deprivation therapy (ADT) at 5 years, according to...
(MedPage Today) Feb 14, 2020 - More than a fourth of men with high-risk prostate cancer had lymph node or distant metastases missed by CT or MRI but detected by PET imaging targeting prostate specific membrane antigen (PSMA), a...
(Yahoo! Finance) Feb 15, 2020 - Mirati Therapeutics, Inc., a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in...
(Decipher) Feb 13, 2020 - Decipher Biosciences today announced that a Decipher GRID molecular subtyping signature, studied in patients from the phase III, randomized controlled trial, CHAARTED, successfully predicted which prostate cancer...
(Dana-Farber) Feb 15, 2020 - Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. Researchers from Dana-Farber Cancer...
Expert Videos

OBR Tweets

Jul 27
Dean Gesme, MD: Trump gave just Congress and manufacturers 30 days to develop and pass a Part B Medicare drug acqui… https://t.co/pK6VjPFbo0

Jul 24
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ZcPRjbtKvL

Jul 24
OBR spoke at length with ASCO's president, Dr. Howard "Skip" Burris, about the pros and cons of #ASCO20's virtual f… https://t.co/9Bq8oJfj5c

Jul 23
A lack of interoperability in the nation's healthcare system has detracted from patient care, leading to poor healt… https://t.co/t6o30WgMjU

Jul 20
William McGivney, PhD: It is with fondness and a smile that I read the story about the distress thermometer now bei… https://t.co/oWDatBpFnu

Jul 15
H. Jack West, MD: Unclear to me why this doesn't raise alarm bells as a conflict of interest. Why is an institution… https://t.co/7pAHP6YnWx

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl